Evaluating the potential of 188Re-SOCTA–trastuzumab as a new radioimmunoagent for breast cancer treatment
To access this article, please choose from the options below
PII: S0969-8051(08)00234-5
doi:10.1016/j.nucmedbio.2008.10.014
© 2009 Elsevier Inc. All rights reserved.
